Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets
Lists
Only you see this
Abstract
Tumor genomic profiling can facilitate the selection of targeted/immunotherapies, as well as clinical trial enrollment, for patients with cervical cancer.
BibTeX
@inproceedings{friedman2023assessing,
author = {Claire F. Friedman and Vignesh Ravichandran and Kathryn Miller and Chad Vanderbilt and Qin Zhou and Alexia Iasonos and Malavika Vivek and Pamela Mishra and Mario M. Leitão and Vance Broach and Yukio Sonoda and Chrisann Kyi and Dmitriy Zamarin and Roisin E. O’Cearbhaill and Jason Konner and Michael F. Berger and Britta Weigelt and Amir Momeni Boroujeni and Kay J. Park and Carol Aghajanian and David B. Solit and Mark T.A. Donoghue},
title = {{Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets}},
booktitle = {Clinical},
year = {2023},
doi = {10.1158/1078-0432.ccr-23-1078},
}Loading related content...